As we have said many, many times - we cover all potential drugs, therapies, vaccine candidates, natural treatments - and the "good" news and the "bad" news about these. We do not promote anything. We report. We do not pick winners and losers. We are not "woke" and do not do cancel culture here.
If you any medical questions, please consult your medical practitioner.
Merck’s antiviral pill reduces hospitalization of Covid patients, a possible game-changer for treatment
By Matthew Herper Oct. 1, 2021
An investigational antiviral pill reduced the chances that patients newly diagnosed with Covid-19 would be hospitalized by about 50%, a finding that could give doctors a desperately needed new way to treat the sick, the drug maker Merck announced Friday.
A five-day course of molnupiravir, developed by Merck and Ridgeback Biotherapeutics, reduced both hospitalization and death compared to a placebo. In the placebo group, 53 patients, or 14.1%, were hospitalized or died. For those who received the drug, 28, or 7.3%, were hospitalized or died.
A simple oral medication to help treat Covid-19 has been an elusive goal since the start of the pandemic. Other drugs, including Gilead’s remdesivir, have also been shown to reduce hospitalizations if given early in the course of disease, but must be given intravenously.
more...
------------------------------------------------------------
Antimicrob Agents Chemother . Human Safety, Tolerability, and Pharmacokinetics of Molnupiravir, a Novel Broad-Spectrum Oral Antiviral Agent with Activity Against SARS-CoV-2
Molecules . Nucleoside Analogs and Nucleoside Precursors as Drugs in the Fight against SARS-CoV-2 and Other Coronaviruses
J Biol Chem . Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template
J Infect Dis . Molnupiravir inhibits the replication of the emerging SARS-CoV-2 variants of concern (VoCs) in a hamster infection model
Curr Opin Virol . Developing a direct acting, orally available antiviral agent in a pandemic: the evolution of molnupiravir as a potential treatment for COVID-19
EBioMedicine . The combined treatment of Molnupiravir and Favipiravir results in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model
If you any medical questions, please consult your medical practitioner.
Merck’s antiviral pill reduces hospitalization of Covid patients, a possible game-changer for treatment
By Matthew Herper Oct. 1, 2021
An investigational antiviral pill reduced the chances that patients newly diagnosed with Covid-19 would be hospitalized by about 50%, a finding that could give doctors a desperately needed new way to treat the sick, the drug maker Merck announced Friday.
A five-day course of molnupiravir, developed by Merck and Ridgeback Biotherapeutics, reduced both hospitalization and death compared to a placebo. In the placebo group, 53 patients, or 14.1%, were hospitalized or died. For those who received the drug, 28, or 7.3%, were hospitalized or died.
A simple oral medication to help treat Covid-19 has been an elusive goal since the start of the pandemic. Other drugs, including Gilead’s remdesivir, have also been shown to reduce hospitalizations if given early in the course of disease, but must be given intravenously.
more...
------------------------------------------------------------
Antimicrob Agents Chemother . Human Safety, Tolerability, and Pharmacokinetics of Molnupiravir, a Novel Broad-Spectrum Oral Antiviral Agent with Activity Against SARS-CoV-2
Molecules . Nucleoside Analogs and Nucleoside Precursors as Drugs in the Fight against SARS-CoV-2 and Other Coronaviruses
J Biol Chem . Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template
J Infect Dis . Molnupiravir inhibits the replication of the emerging SARS-CoV-2 variants of concern (VoCs) in a hamster infection model
Curr Opin Virol . Developing a direct acting, orally available antiviral agent in a pandemic: the evolution of molnupiravir as a potential treatment for COVID-19
EBioMedicine . The combined treatment of Molnupiravir and Favipiravir results in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model
Comment